Approved indications: Vosevi is indicated for adults with chronic HCV genotypes 1–6, without cirrhosis or with compensated cirrhosis, who have previously been treated with a direct-acting antiviral regimen containing an NS5A inhibitor, or for adults with genotype 1a or 3 infection who were previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.

Off-label uses: Off-label use is uncommon and generally limited to specialist-guided retreatment of difficult HCV cases when other recommended options are unsuitable, with support mainly from small studies and extrapolation from its approved use in DAA-experienced patients.

Efficacy expectations: In clinical trials of adults who had failed prior DAA regimens, once-daily Vosevi for 12 weeks achieved sustained virologic response (cure) rates of roughly 95–98%, with viral load usually becoming undetectable within the first 4–8 weeks; compared with other modern oral HCV combinations it offers similar overall cure rates but is mainly used as a highly effective “salvage” option after previous therapies such as sofosbuvir/velpatasvir or ledipasvir/sofosbuvir have not worked, rather than as first-line treatment.

Typical dosing: For eligible adults with chronic hepatitis C, the usual dose is one Vosevi tablet (400 mg sofosbuvir/100 mg velpatasvir/100 mg voxilaprevir) taken by mouth once daily with food for 12 weeks, provided there is no decompensated cirrhosis.

How to take the medicine: Swallow the tablet whole with food at about the same time each day, do not crush or chew it, and continue taking it every day for the full prescribed course even if you feel well and your symptoms improve.

Special dosing instructions: No routine dose adjustment is needed for older adults or for kidney impairment, including dialysis, but Vosevi is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or prior hepatic decompensation; all patients should be evaluated for hepatitis B coinfection before starting, and dosing may need to be separated from or adjusted with certain acid-reducing medicines or other drugs that interact with Vosevi.

Missed-dose guidance: If you miss a dose and remember on the same day, take it as soon as you remember with food and then take the next dose at the usual time; if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule, and never take two doses at once to make up for a missed tablet.

Overdose: If more than the prescribed number of tablets are taken, contact a healthcare provider or Poison Control (1-800-222-1222 in the U.S.) right away, and seek emergency care immediately if severe symptoms such as fainting, chest pain, or difficulty breathing occur.

Common side effects: The most frequent side effects are headache, tiredness, diarrhea, and nausea, which are usually mild to moderate in severity, tend to start in the first days of therapy, and often improve as the 12-week course continues.

Serious or rare adverse effects: Serious problems can include reactivation of hepatitis B in patients with current or past HBV infection, worsening liver function or liver failure in those with advanced liver disease, severe allergic reactions, and dangerous slowing of the heart rate when Vosevi is taken with amiodarone; symptoms such as yellowing of the skin or eyes, severe abdominal pain, dark urine, confusion, fainting, chest pain, or shortness of breath require immediate medical attention.

Warnings and precautions: Vosevi is approved only for adults, and its safety and effectiveness in children are not established; it is not recommended for patients with moderate or severe hepatic impairment (Child-Pugh B or C) or a history of decompensated cirrhosis, and although no dose change is routinely needed in kidney disease (including dialysis), experience in severe renal impairment is more limited, so closer monitoring may be used. All patients should be tested for hepatitis B before starting treatment, and pregnancy and breastfeeding require careful discussion because human data are limited and use is generally avoided unless the potential benefit clearly outweighs risks.

Comparative safety: Overall tolerability is similar to other all-oral direct-acting antiviral regimens, but the inclusion of the protease inhibitor voxilaprevir is associated with somewhat higher rates of gastrointestinal effects like nausea and diarrhea and makes the drug unsuitable for decompensated cirrhosis, so simpler regimens are preferred when prior treatment failure has not occurred.

Safety reporting and information: Side effects can be reported to the FDA MedWatch program (online or at 1-800-FDA-1088), and updated safety information and communications are available through FDA resources and the product’s prescribing information.

Major drug interactions: Vosevi must not be used with rifampin and is not recommended with strong enzyme or transporter inducers such as carbamazepine, phenytoin, phenobarbital, rifabutin, rifapentine, or the herbal product St John’s wort, because these can greatly lower Vosevi levels and lead to loss of antiviral effect.

Other important interactions: Combining Vosevi with amiodarone can cause serious, sometimes life-threatening slowing of the heart rate; certain HIV medicines (such as efavirenz and some boosted protease inhibitor regimens), specific cholesterol-lowering drugs (especially rosuvastatin or pitavastatin), cyclosporine, and some seizure medications may raise or lower drug levels and require avoidance, dose adjustment, or close monitoring. Acid-reducing agents (antacids, H2-blockers, proton-pump inhibitors) can reduce velpatasvir exposure, so timing and dosing may need to be modified based on prescriber instructions.

OTC medicines, supplements, and foods: Patients should check with a clinician or pharmacist before starting new over-the-counter drugs or herbal products, particularly acid reducers or supplements containing St John’s wort; there are no specific food restrictions with Vosevi, but alcohol is generally discouraged in people with hepatitis C because it can worsen liver damage and counteract treatment benefits.

Precautions for use: Vosevi is intended for adults with chronic HCV without decompensated cirrhosis and is not recommended in moderate or severe hepatic impairment (Child-Pugh B or C) or in those with prior hepatic decompensation; it should be used cautiously in patients with significant heart disease, prior hepatitis B infection, or complex polypharmacy due to interaction risks.

Monitoring needs: Before and during therapy, clinicians typically monitor liver function tests, bilirubin, and, when indicated, hepatitis B markers and kidney function, and they follow HCV viral load to document cure; if Vosevi must be used with amiodarone, heart rhythm monitoring is recommended, especially early in treatment.

Q: What is Vosevi and what is it used for?
A: Vosevi is an oral combination of three direct-acting antiviral medicines used in adults to treat chronic hepatitis C infection (genotypes 1–6) who have already tried and not been cured by certain previous hepatitis C treatments.

Q: How effective is Vosevi at curing hepatitis C?
A: In adults whose previous direct-acting antiviral regimens failed, a 12-week course of Vosevi cures (achieves sustained virologic response) in about 95–98% of patients when taken exactly as prescribed.

Q: How quickly will I feel better or see results on Vosevi?
A: Many people notice few symptoms from hepatitis C itself, but blood tests usually show a rapid drop in viral load within weeks, and you are considered cured if the virus remains undetectable 12 weeks after finishing treatment.

Q: Can I drink alcohol while taking Vosevi?
A: There is no direct drug–alcohol interaction, but alcohol can further damage the liver, so most clinicians advise avoiding or strictly limiting alcohol during and after Vosevi therapy.

Q: What should I do if I miss a dose of Vosevi?
A: If you remember on the same day, take the missed tablet with food as soon as possible and then take your next dose at the usual time, but if it is nearly time for the next dose just skip the missed one and never double up.

Q: Is Vosevi safe during pregnancy or breastfeeding?
A: The safety of Vosevi in pregnancy and breastfeeding is not well established, so treatment is usually timed to avoid these periods when possible, and any decision to use it should be made carefully with your liver specialist and obstetric provider.

Storage: Store Vosevi at room temperature below 86°F (30°C), in the original tightly closed bottle with the desiccant, and protect it from moisture; keep it out of the reach of children.

Handling: Do not remove the drying packet from the bottle, avoid storing tablets in pill boxes unless your prescriber or pharmacist advises it, and always keep the label and instructions with the medicine.

Disposal: When treatment is finished or tablets expire, ask a pharmacist about local medicine take-back programs or follow community guidance for household medicine disposal; do not flush tablets down the toilet unless specifically instructed.